Recently, we posted about misadventures of the leadership of biotechnology giant Genzyme. Although the company has long priced its drug Cerezyme for the rare Gaucher's disease at a stratospheric level, it did not sufficiently reinvest money in its manufacturing facility for the drug. Deferred maintenance at a production facility running at maximum capacity has apparently lead to two different kinds of contamination problems, forcing a shut-down of the plant, and now a shortage of the drug. For this, Genzyme CEO Henri Termeer...
Popular products
Post new comment